Skip to content

MDMA research published in 2016

Page 3 of 4: studies 41 to 60 of 71, newest first. Back to the MDMA overview

Studies

Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants

Frontiers in Neuroscience April 19, 2016 Cristina Miliano, Giovanni Serpelloni, Claudia Rimondo et al. 195 citations

New psychoactive substances (NPS) are a heterogeneous and rapidly evolving class of molecules available on the global illicit drug market (e.g smart shops, internet, "dark net") as a substitute for controlled substances. The use of NPS, mainly consumed along with other drugs of abuse and/or alcohol, has resulted in a significantly growing number of mortality and emergency admissions for...

DOI: 10.3389/fnins.2016.00153 (opens in new tab) MDMA Addiction Synthetic cannabinoids Neuropharmacology +5

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.

The Lancet Psychiatry April 5, 2016 Michael C Mithoefer, Charles S. Grob, Timothy D Brewerton 237 citations

4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxymethamfetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as...

MDMA self-administration fails to alter the behavioral response to 5-HT(1A) and 5-HT(1B) agonists.

Psychopharmacology April 2016 Dane Aronsen, Susan Schenk

Regular use of the street drug, ecstasy, produces a number of cognitive and behavioral deficits. One possible mechanism for these deficits is functional changes in serotonin (5-HT) receptors as a consequence of prolonged 3,4 methylenedioxymethamphetamine (MDMA)-produced 5-HT release. Of particular interest are the 5-HT(1A) and 5-HT(1B) receptor subtypes since they have been implicated in...

Repeated administration of the 5-HT₁B/₁A agonist, RU 24969, facilitates the acquisition of MDMA self-administration: role of 5-HT₁A and 5-HT₁B receptor mechanisms.

Psychopharmacology April 2016 Dane Aronsen, Natasha Bukholt, Susan Schenk

3,4 Methylenedioxymethamphetamine (MDMA) preferentially stimulates the release of serotonin (5-HT) that subsequently produces behavioral responses by activation of post-synaptic receptor mechanisms. The 5-HT1A and 5-HT1B receptors are both well localized to regulate dopamine (DA) release, and have been implicated in modulating the reinforcing effects of many drugs of abuse, but a role in...

Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users.

Neuroscience & Biobehavioral Reviews April 2016 Carl Alexander Roberts, Andrew Jones, Catharine Montgomery

We conducted a meta-analysis on the available data from studies investigating SERTs in ecstasy users and polydrug using controls. From 7 studies we compared data from 157 ecstasy users and 148 controls across 14 brain regions. The main effect suggested ecstasy/MDMA related SERT reductions (SMD=0.52, 95% CIs [0.40, 0.65]; Z=8.36, p<.01, I(2)=89%). A significant effect of subgroups (X(2)=37.41,...

Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting.

Journal of Psychopharmacology April 2016 Matthew J. Baggott, Jeremy Coyle, Jennifer D. Siegrist et al.

The drug 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy", "molly") is a widely used illicit drug and experimental adjunct to psychotherapy. MDMA has unusual, poorly understood socioemotional effects, including feelings of interpersonal closeness and sociability. To better understand these effects, we conducted a small (n=12) within-subjects double-blind placebo controlled study of the...

Neurochemical substrates of the rewarding effects of MDMA: implications for the development of pharmacotherapies to MDMA dependence.

Behavioural Pharmacology April 2016 Concepción Roger-Sánchez, María P García-Pardo, Marta Rodríguez‐arias et al.

In recent years, studies with animal models of reward, such as the intracranial self-stimulation, self-administration, and conditioned place preference paradigms, have increased our knowledge on the neurochemical substrates of the rewarding effects of 3,4-methylenedioxymetamphetamine (MDMA) in rodents. However, pharmacological and neuroimaging studies with human participants are scarce....

Effect of Some Psychoactive Drugs Used as ‘Legal Highs’ on Brain Neurotransmitters

Neurotoxicity Research April 1, 2016 Krystyna Gołembiowska, Alexandra Jurczak, Katarzyna Kamińska et al.

New psychoactive “designer drugs” are synthetic compounds developed to provide similar effects to illicit drugs of abuse, but not subjected to legal control. The rapidly changing legal status of novel psychoactive drugs triggers the development of new compounds, analogs of well-known amphetamine or mescaline. New designer drugs used as substitutes in ecstasy pills are the least investigated and...

Potentiation of Ecstasy-induced hyperthermia and FAT/CD36 expression in chronically exercised animals.

Temperature March 30, 2016 Sandra L Hrometz, Jeremy A Ebert, Karen E Grice et al.

Fatal hyperthermia as a result of 3,4-methylenedioxymethamphetamine (MDMA) use involves non-esterified free fatty acids (NEFA) and the activation of mitochondrial uncoupling proteins (UCP). NEFA gain access into skeletal muscle via specific transport proteins, including fatty acid translocase (FAT/CD36). FAT/CD36 expression is known to increase following chronic exercise. Previous studies have...

The History of MDMA as an Underground Drug in the United States, 1960–1979

Journal of Psychoactive Drugs March 3, 2016 Torsten Passie, Udo Benzenhöfer 56 citations

MDMA (3,4-methylenedioxy-methylamphetamine, a.k.a. "ecstasy") was first synthesized in 1912 and resynthesized more than once for pharmaceutical reasons before it became a popular recreational drug. Partially based on previously overlooked U.S. government documentation, this article reconstructs the early history of MDMA as a recreational drug in the U.S. from 1960 to 1979. According to the...

3,4‐methylenedioxymethamphetamine increases excitability in the dentate gyrus: role of 5HT2A receptor‐inducedPGE2 signaling

Journal of Neurochemistry March 1, 2016 Stuart A. Collins, Courtney L Huff, Nicolas Chiaia et al.

Abstract: 3,4‐methylenedioxymethamphetamine (MDMA) is a widely abused psychostimulant, which causes release of serotonin in various forebrain regions. Recently, we reported thatMDMAincreases extracellular glutamate concentrations in the dentate gyrus, via activation of 5HT2A receptors. We examined the role of prostaglandin signaling in mediating the effects of 5HT2A receptor activation on the...

Prevention of drug priming- and cue-induced reinstatement of MDMA-seeking behaviors by the CB1 cannabinoid receptor antagonist AM251.

Drug and Alcohol Dependence March 1, 2016 Yoko Nawata, Kiyoyuki Kitaichi, Tsuneyuki Yamamoto

3,4-Methylenedioxymethamphetamine (MDMA), a methamphetamine (METH) derivative, exhibits METH-like actions at monoamine transporters and positive reinforcing effects in rodents and primates. The purposes of the present study were to determine whether cross-reinstatement would be observed between MDMA and METH and if the cannabinoid receptor, a receptor known to play critical roles in the brain...

DOI: 10.1016/j.drugalcdep.2015.12.016 (opens in new tab) Full text (opens in new tab) MDMA Cb1 cannabinoid receptor Drug-seeking behavior Methamphetamine +1

The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)

European Psychiatry March 1, 2016 Laura Orsolini, Alessandro Valchera, Duccio Papanti et al. 3 citations

Introduction Hallucinogen Persisting Perception Disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, including cannabis, MDMA (methylenedioxymethamphetamine), psilocybin, mescaline and other psychostimulants....

Can ecstasy treat the agony of PTSD?

European Psychiatry March 1, 2016 M. Mithoefer

IntroductionTwo serotonin reuptake inhibitors (SSRIs) have received FDA indication for treatment of PTSD, however the effectiveness of pharmacotherapy for PTSD is limited. Psychotherapy, including several well established evidence based methods, is the mainstay of PTSD treatment. Despite advances in this area, a significant percentage of PTSD patients are refractory to existing treatments....

DOI: 10.1016/j.eurpsy.2016.01.798 (opens in new tab) PTSD Treatment MDMA-Assisted Therapy Mental health improvement Clinical research

Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective

PLoS One February 23, 2016 Kim P. C. Kuypers, Eef L. Theunissen, Janelle H. P. van Wel et al. 23 citations

BACKGROUND: Ecstasy use has been associated with short-term and long-term memory deficits on a standard Word Learning Task (WLT). The clinical relevance of this has been debated and is currently unknown. The present study aimed at evaluating the clinical relevance of verbal memory impairment in Ecstasy users. To that end, clinical memory impairment was defined as decrement in memory performance...

Religion and Ecstasy in Seventeenth Century Italy

Inquiry@Queen's Undergraduate Research Conference Proceedings February 5, 2016 Emilija Babich

In the seventeenth century, the supremacy of the Catholic Church was being threatened both by science and by the growth of Protestantism. Rome, as the only remaining centre for Catholicism, needed to reassert its authority and reclaim those who had lost their faith. As a result, religious artistic production of the seventeenth century took on a spectacular and theatrical character that sought...

Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method.

Medical Hypotheses February 1, 2016 Thomas S. Ray 6 citations

The drug MDMA, commonly known as ecstasy, produces a specific and distinct open hearted mental state, which led to the creation of a new pharmacological class, "entactogens". Extensive literature on its mechanisms of action has come to characterize MDMA as a "messy" drug with multiple mechanisms, but the consensus is that the distinctive entactogenic effects arise from the release of...

DOI: 10.1016/j.mehy.2015.12.018 (opens in new tab) Full text (opens in new tab) Mental organs Neuron groups Specific mental states Complex brain states +10

Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine.

Toxicology Letters January 22, 2016 Andrea E. Steuer, Martina I. Boxler, Lorena Stock et al.

Neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA) is still controversially discussed. Formation of reactive oxygen species e.g. based on elevated dopamine (DA) concentrations and DA quinone formation is discussed among others. Inhibition potential of MDMA metabolites regarding neurotransmitter degradation by catechol-O-methyltransferase and sulfotransferase was described previously....

Oxytocin receptor gene variation predicts subjective responses to MDMA

Social Neuroscience January 20, 2016 Anya K. Bershad, Jessica Weafer, Matthew G. Kirkpatrick et al. 35 citations

3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") enhances desire to socialize and feelings of empathy, which are thought to be related to increased oxytocin levels. Thus, variation in the oxytocin receptor gene (OXTR) may influence responses to the drug. Here, we examined the influence of a single OXTR nucleotide polymorphism (SNP) on responses to MDMA in humans. Based on findings that...

DOI: 10.1080/17470919.2016.1143026 (opens in new tab) MDMA Ecstasy Oxytocin receptor Single-nucleotide polymorphism +2

Trajectories of drug use among French young people: Prototypical stages of involvement in illicit drug use

Journal of Substance Use January 20, 2016 Stéphanie Baggio, Stanislas Spilka, Joseph Studer et al. 9 citations

Aims: This study investigated patterns and trajectories of substance use, with a special focus on illicit drugs other than cannabis. It examined both patterns and trajectories of use among a general population-based sample. Methods: We used data from the 2011 French ESCAPAD survey of French 17-year-olds to assess exposure and age of initiation of 14 licit and illicit drugs (N=23,882). Latent...